万泰生物连跌10天，易方达基金旗下1只基金位列前十大股东

Core Insights - Wantai Biological Pharmacy Company has experienced a continuous decline in stock price for 10 consecutive trading days, with a cumulative drop of -7.01% [1] - The company specializes in the research and production of biological diagnostic reagents and vaccines, established in 1991 [1] - E Fund's HuShen 300 Pharmaceutical ETF, one of Wantai's top ten shareholders, reduced its holdings in the second quarter of this year [1] Financial Performance - The year-to-date return for the E Fund HuShen 300 Pharmaceutical ETF is 12.77%, ranking 857 out of 2519 in its category [1][2] - The ETF has shown varying performance over different time frames, with a near-term decline of -2.19% over the past week, but a positive return of 10.74% over the past month [2] - Compared to the average of its peers, the ETF's performance is slightly above average for the year, with a return of 12.24% [2] Management Information - The fund manager of E Fund HuShen 300 Pharmaceutical ETF is Yu Haiyan, who has extensive experience in investment management [4][5] - Yu Haiyan holds a master's degree in economics and has previously worked in various roles within the financial sector, including credit risk analysis and fund management [5]